Belite Bio, Inc (BLTE) Net Income towards Common Stockholders (2022 - 2026)

Belite Bio (BLTE) has reported Net Income towards Common Stockholders for 5 consecutive years, with $0.68 the latest figure, recorded in Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 251.11% year-over-year to $0.68; the TTM figure through Mar 2026 stood at -$1.17 (down 631.25% YoY), while the FY2025 annual figure was $2.31, up 95.76% from the prior year.
• Net Income towards Common Stockholders came in at $0.68 for Q1 2026 at Belite Bio, up from -$0.7 in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $0.68 in Q1 2026, with the low at -$0.7 in Q4 2025.
• Average Net Income towards Common Stockholders over 5 years is -$0.16, with a median of -$0.26 recorded in 2022.
• Across the five-year window, Net Income towards Common Stockholders jumped 500.0% in 2023 and plunged 332.14% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$0.27 in 2022, then rose by 7.41% to -$0.25 in 2023, then jumped by 228.0% to $0.32 in 2024, then slumped by 318.75% to -$0.7 in 2025, then surged by 197.14% to $0.68 in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $0.68, -$0.7, and -$0.65 for Q1 2026, Q4 2025, and Q3 2025 respectively.